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Development of an effective vaccine for severe acute respiratory syndrome (SARS) remains to be a priority to prevent possible re-emergence
of SARS coronavirus (SARS-CoV). We previously demonstrated that the receptor-binding domain (RBD) of SARS-CoV S protein is a major
target of neutralizing antibodies. This suggests that the RBD may serve as an ideal vaccine candidate. Recombinant adeno-associated virus (rAAV)
has been proven to be an effective system for gene delivery and vaccine development. In this study, a novel vaccine against SARS-CoV was
developed based on the rAAV delivery system. The gene encoding RBD was cloned into a pAAV-IRES-hrGFP plasmid. The immunogenicity
induced by the resulting recombinant RBD-rAAV was evaluated in BALB/c mice. The results demonstrated that (1) a single dose of RBD-rAAV
vaccination could induce sufficient neutralizing antibody against SARS-CoV infection; (2) two more repeated doses of the vaccination boosted the
neutralizing antibody to about 5 times of the level achieved by a single dose of the immunization and (3) the level of the antibody continued to
increase for the entire duration of the experiment of 5.5 months. These results suggested that RBD-rAAV is a promising SARS candidate vaccine.
© 2006 Elsevier Inc. All rights reserved.Keywords: Adeno-associated virus; SARS-CoV; Spike protein; Receptor-binding domain; Neutralizing antibodies; VaccinesIntroduction
Severe acute respiratory syndrome (SARS) coronavirus
(SARS-CoV) has been identified as the etiological agent of
the newly emerging infectious disease SARS (Drosten et al.,
2003; Ksiazek et al., 2003; Marra et al., 2003; Peiris et al., 2003;
Rota et al., 2003). Although SARS appears to have been
successfully contained, re-emergence of the disease cannot be
ruled out. This is supported by the fact that four laboratory-
acquired and four community-acquired SARS cases were
reported in Singapore, Taiwan and China after the SARS⁎ Corresponding authors. Y. Zhou is to be contacted at fax: +86 10 6381 5259.
B.-J. Zheng, fax: +8 52 2855 1241.
E-mail addresses: yszhou@bmi.ac.cn (Y. Zhou), bzheng@hkucc.hku.hk
(B.-J. Zheng).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.03.049outbreak (www.who.int/csr/sars/en). Therefore, development of
effective vaccines against SARS is urgently needed.
SARS-CoV is a single-stranded positive RNA virus, whose
genome encodes nonstructural replicase polyprotein (rep), and
structural proteins such as spike (S), envelope (E), membrane
(M) and nucleocapsid (N) (Anand et al., 2003; Marra et al.,
2003; Rota et al., 2003). S protein recognizes and binds to host
receptors, and the conformational changes induced in this viral
protein would then facilitate fusion between the viral envelope
and the host cell membranes, thus S plays pivotal roles in viral
infection and pathogenesis (Hofmann et al., 2004; Holmes,
2003a; Yu et al., 2003; Zheng et al., 2005). S protein is a type I
transmembrane glycoprotein consisting of S1 and S2 domains
(Bosch et al., 2003; Holmes and Enjuanes, 2003b; Krokhin et
al., 2003; Ying et al., 2004; Fig. 1). The S1 domain determines
the host cell tropism by attaching to cell receptors, and the S2
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fusion (Bosch et al., 2003; Gallagher and Buchmeier, 2001).
Angiotensin-converting enzyme 2 (ACE2) has been identified
as a functional receptor for SARS-CoV (Dimitrov, 2003; Li et
al., 2003; Prabakaran et al., 2004), and a 193-aa fragment
containing residues 318–510 of the S1 region is found to be
the minimal receptor-binding domain (RBD) (Babcock et al.,
2004; Wong et al., 2003; Xiao et al., 2003; Fig. 1). A second
major property of SARS-CoV S protein is that it induces
neutralizing antibodies and protective immunity (Bisht et al.,
2004; Buchholz et al., 2004; Bukreyev et al., 2004; Yang et al.,
2004). Yang et al. (2004) reported that a DNA vaccine
encoding S protein was able to induce T-cell and neutralizing-
antibody responses (neutralizing antibody titers range from
1:50 to 1:150). They proved that protection of mice against
SARS-CoV challenge was mediated by neutralizing antibodies
but not a T-cell-dependent mechanism. Traggiai et al. (2004)
demonstrated that protective immunity in mice could be
achieved by sole administration of neutralizing monoclonal
antibodies specific for S protein. These data suggest that an
effective SARS vaccine can be developed based on its ability
to induce neutralizing antibodies. We previously reported that
RBD of SARS-CoV S protein was able to elicit potent
neutralizing antibodies in rabbits (He et al., 2004a). Further-
more, RBD has also been found to be an immunogenic domain
of SARS-CoV, which induced neutralizing antibodies in
SARS-CoV infected patients (He et al., 2004b). Therefore, S
protein, especially RBD in the S1 domain, is a good target forFig. 1. Schematic diagram of S protein of SARS-CoVand pRBD-AAV. The structure o
(13 aa) and from 318 to 510 aa (193 aa), respectively. The S2 domain contains functio
and 193 aa RBD of SARS-CoV S protein was amplified and ligated into the pAAVdeveloping vaccines against SARS (He et al., 2004b; Yang et
al., 2004).
Adeno-associated virus (AAV) is a powerful delivery
vector that is widely used in gene therapy (Chao et al., 2002;
Kaspar et al., 2002; Tsai et al., 2002). With high transduction
efficiency, minimal viral toxicity, broad range of infectivity
and little pathogenesis in humans, the AAV system has been
successfully applied in studying gene and immune therapies
for many diseases (Keir et al., 1999; Lieber, 2003).
Furthermore, the long-term gene transfer and expression in
a variety of cell types and organs have made this system an
ideal choice for developing recombinant vaccines (Tomar et
al., 2003).
In the present study, we used AAV as a vector to deliver a
gene expressing RBD of SARS-CoV S protein (RBD-rAAV).
The effects of single dose and multiple doses of the RBD-
rAAV vaccination were evaluated in BALB/c mice for
inducing SARS-CoV-specific antibodies, especially neutraliz-
ing antibodies.
Results
Generation of the recombinant AAV in transfected 293T cells
SARS-CoV S protein is a glycoprotein consisting of an S1
and an S2 domain. The S1 domain contains the signal
peptide (SP) at the N-terminus and RBD at aa 318 to 510.
The S2 domain contains heptad repeat 1 and 2 (HR1 andf SARS-CoV S protein (A). In the S1 domain, SP and RBD range from 1 to 13 aa
nal domains HR1, HR2 and TM. DNA encoding 24 aa of the CD5 signal peptide
-IRES-hrGFP plasmid to construct the recombinant pRBD-AAV vector (B).
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construction of the pRBD-AAV vector, the nucleotide
sequence encoding SP was replaced by the CD5 and the
latter was ligated to the RBD sequence of SARS-CoV S,
and the chimeric gene was subcloned into the multiple
cloning sites (MCS) of the pAAV-IRES-hrGFP plasmid
(Stratagene, USA) (Fig. 1B). The resulting pRBD-AAV
plasmid, or the blank pAAV plasmid, was co-transfected into
293T cells together with pAAV-RC and pHelper plasmids to
produce AAV, which harbors the chimeric CD5-RBD gene
(RBD-rAAV) or that which does not harbor the chimeric
gene (blank AAV). Intense fluorescence of the humanized
recombinant green fluorescent protein (hrGFP) in RBD-AAV
(Fig. 2A) and blank AAV (Fig. 2B) was observed in the
transfected cells under a fluorescence microscopy at 72 h
post-transfection, illustrating a high transfection efficiency of
the viral plasmids in 293T cells. The yield of either the
RBD-rAAV or the blank AAV from the respective transfected
cells harvested from 30 × 100 mm tissue culture dishes was
purified and the titer was estimated by real-time quantitative
PCR to be 5 × 1012 viral particles/ml.
Transduction efficiency of the recombinant AAV
Fig. 3 compares the transduction of RBD-rAAV and
blank AAV in 293T and HeLa cells. In this experiment,
293T and HeLa cells were inoculated with serial dilution of
the viruses and after 72 h of incubation, the extent of
infection with either virus was assessed by the level of GFP
(hrGFP) expressed by these cells, using fluorescence
microscopy and flow cytometry analysis. Fluorescence
microscopy shows that 293T cells infected with the rAAVs
(Fig. 3A) are more numerous than HeLa cells (Fig. 3B). As
shown in Fig. 3C, flow cytometry analysis estimates that
that 98.4% of 293T cells was infected with RBD-rAAV and
98.2% was infected with blank AAV and this is substantially
higher than the levels of infection achieved in HeLa cells
with RBD-rAAV (22.6%) or blank AAV (21.7%). These
results confirm the findings by Romano et al. (2000),
showing that the infection efficiency of the AAV vector
differs for different cells.
In another experiment, percentage of infected cells was
enumerated at different times after infection (Fig. 3D). TheFig. 2. RBD-rAAV production in 293T cells. After 293T cells were transfected
by pRBD-AAV (A) or blank pAAV (B) together with their helper plasmids for
72 h, intense fluorescence of hrGFP was observed under fluorescence
microscopy (40×).results showed that percentage of RBD-rAAV-infected 293T
cells detected at different times closely parallels the
percentage of blank AAV-infected 293T cells (a), as does
the percentage of HeLa cells infected with either of these
viruses (b). This shows that the RBD insert did not affect the
efficiencies of the rAAV infection and expression.
Expression of the RBD protein by the recombinant RBD-rAAV
Expression of RBD in RBD-rAAV infected HeLa cells was
detected by an immunofluorescence assay (IF) and a Western
blot assay. The IF results showed that a monoclonal antibody
specific to SARS-CoV S1 (McAb-S1) reacted with the cells
infected by RBD-AAV (Fig. 4A), but not with those infected
by blank AAV (Fig. 4B). The expression of RBD was also
detected by Western blot in lysate of cells infected with RBD-
rAAV but not in lysate of cells infected with blank AAV (Fig.
4C). These results demonstrated that RBD-rAAV was able to
efficiently express the inserted RBD gene in the infected
cells.
Single dose of RBD-rAAV vaccination induced sufficient
SARS-CoV-specific antibody responses with neutralizing
activity in mice
Groups of 5 to 10 BALB/c mice were vaccinated with
single dose of RBD-rAAV, blank AAV (negative control) or
with inactivated SARS-CoV suspended in PBS or in adjuvant
Alum (positive control). The animals were bled before
immunization and at 1, 2 and 4 months post-vaccination.
Levels of SARS-CoV-specific antibodies in these serum
samples were determined by ELISA. As shown in Fig. 5A,
the titers of SARS-CoV-specific antibodies in the sera from
single dose of RBD-rAAV immunized mice reached
1:680 ± 120 (mean ± SE) at 1 month and slightly increased
to 1:880 ± 160 at 4 months post-vaccination. By comparison,
the levels of SARS-CoV antibodies induced by the inactivated
virus vaccination peaked earlier (2 month post-immunization)
and at a slightly low level (1:686 ± 175 with Alum, P > 0.05)
or at a significantly low level (1:384 ± 64 without Alum,
P < 0.05) at 2 months post-immunization. SARS-CoV
neutralizing activity in the mouse sera was further tested by
a neutralization assay in Vero E6 cells according to method
described by Qu et al. (2005). In animals vaccinated with
RBD-rAAV, Fig. 5B shows that the neutralizing antibody
level rose continuously from 1:48 ± 8 at 1 month to
1:108 ± 20 at 4 months post-vaccination. By comparison, the
antibody level of animals given the inactivated virus
vaccination peaked earlier, at 2 months after immunization.
The peak level of neutralizing antibody of the animals
vaccinated with the RBD-rAAV is similar as that of
vaccinated with the inactivated virus suspended in Alum
(1:109 ± 18, P > 0.05), but it is almost 3-fold higher than that
was given the inactivated virus suspended in PBS (1:42 ± 10,
P < 0.05). No SARS-CoV neutralizing antibodies (<1:20)
could be detected in the mouse sera from blank AAV
immunized group. The results indicated that although the
Fig. 3. Detection of RBD-rAAV transduction efficiency by fluorescence microscopy and flow cytometry analysis. The infection of RBD-rAAVand blank AAV in 293T
(A) and HeLa cells (B) was detected at 72 h post-infection under fluorescence microscopy (100×). The infection rates of the AAVs in these two cell lines were further
measured at 72 h post-infection by a flow cytometry analysis (C). The top right of each histogram shows the mean percentage of GFP positive cells in analyzed cell
populations from two independent experiments. Black lines indicate the non-infected cells and red lines indicate the blank AAV-infected cells, while blue lines indicate
the RBD-rAAV infected cells. The infection rates of RBD-rAAVand blank AAV in 293T (a) and HeLa cells (b) were further tested at different time points from 1 to 4
days (D).
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antibody than vaccination with SARS-CoV plus Alum at 1–2
months after immunization, it can deliver a prolonged effect
with an increasing neutralizing antibody titer at 4 months
post-vaccination, which was similar or higher than inactivated
virus vaccination with or without Alum (P > 0.05).Repeated vaccinations of RBD-rAAV effectively induced high
levels of SARS-CoV-specific antibodies with neutralizing activity
In a further experiment, groups of 5 mice were given 2
repeated doses of RBD-rAAV, blank AAV (negative control) or
with inactivated SARS-CoV with or without adjuvant Alum
Fig. 5. Evaluation of specific antibody responses in single dose of RBD-rAAV-
vaccinated mice. The mice were i.m.-immunized respectively with one dose of
RBD-rAAV, blank AAVand inactivated SARS-CoV with (In-SCoV + Alum) or
without (In-SCoV) Alum. Serum samples were collected from the mice at pre-
vaccination (0 month), 1, 2 and 4 months post-immunization. SARS-CoV-
specific antibodies in the serum samples were detected by ELISA using the
commercial SARS-CoV antibody detection kit (A). The neutralizing antibody
titers in the sera were measured by a neutralization assay (B). The experiments
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over a period of 5.5 months following the first dose. In the
animals given the RBD-rAAV vaccine, the level of the SARS-
CoV-specific antibody determined by ELISA increased contin-
uously throughout the experiment to reach a titer of 1:5120 ± 320
at 5.5 months post-vaccination (Fig. 6A). In animals given the
inactivated virus, the antibody levels reached the peak
(1:3584 ± 627 without Alum and 1:4754 ± 366 with Alum) at
4 months post-vaccination. The antibody level determined at the
end of the experiment 5.5 months after the first dose was slightly
higher for animals, which were given the RBD-rAAV vaccine
than those which were given the inactivated virus, but the
difference was not statistically significant (P > 0.05).
The neutralizing antibody level in RBD-rAAV group of
animals also rose continuously throughout the duration of the
experiment of 5.5 months, as did the levels of ELISA antibody,
whereas the antibody level of the animals receiving the inacti-
vated virus vaccines peaked on the 4th month. At the end of the
experiment, 5.5 months after the first dose, the neutralizing
antibody level of RBD-rAAV group was 1:512 ± 78, which is
similar as the peak antibody levels of animals given the inacti-
vated virus vaccine (1:512 ± 78 without Alum and 1:640 ± 121
with Alum), and it is 5 times higher than the antibody level
induced by a single dose of this vaccine (see Fig. 6B).
Sera from RBD-rAAV-vaccinated mice suppressed RBD
binding to the receptor ACE2
Sera from the mice immunized with RBD-rAAV were
detected for the inhibitory activity against binding of RBD toFig. 4. Detection of the RBD expression in RBD-rAAV infected cells by an
immunofluorescence assay and Western blot analysis. Expression of RBD in RBD-
rAAV (A) and blank AAV (B) infected HeLa cells were tested by an immunofluores-
cence assay. TheRBD expressionwas also detected byWestern blot (C). Lanes 1 and
3, RBD-rAAV-infected HeLa and 293T cell lysates; lanes 2 and 4, blank AAV-
infected HeLa and 293Tcell lysates. The molecular marker (kDa) is indicated on the
left. The molecular mass of the expressed RBD protein was about ∼34 kDa.
were repeated four times for the RBD-rAAV group and two times for the other
groups. The data were presented as the mean values ± SE.SARS-CoV receptor ACE2 by a competitive assay. As shown in
Fig. 7, the sera from all of five RBD-rAAV immunized mice
were able to suppress more than 90% of RBD binding to ACE2,
while none of the pre-immunized sera and sera from blank AAV
immunized mice inhibited the binding. These results concur
with occurrence of SARS-CoV neutralizing antibody, implying
that RBD-rAAV vaccination could evoke protective immunity
against the virus.
Discussion
Development of SARS vaccines is an urgent requirement in
preventing re-emergence of SARS. Several approaches for
developing SARS vaccines have been reported. These include
inactivated vaccines (He et al., 2004a; Qu et al., 2005), DNA
vaccines (Yang et al., 2004; Zeng et al., 2004), recombinant
protein-based vaccines (Bisht et al., 2004, 2005; He et al.,
2004b), the attenuated modified vaccinia virus Ankara (MVA)
based vaccine (Chen et al., 2005), the adenovirus-based vaccine
(Gao et al., 2003a,b) and the rhabdovirus-based vaccine (Faber
et al., 2005). These candidate vaccines could induce SARS-
CoV-specific immune responses and/or elicit protective neu-
tralizing antibody responses in immunized animals. In this
study, we constructed another SARS vaccine based on the AAV
Fig. 6. Detection of specific antibody responses in three doses of RBD-rAAV-
vaccinated mice. SARS-CoV-specific antibody responses in mice vaccinated
with three doses of RBD-rAAV or controls were tested by ELISA (A) and
neutralization assay (B). Serum samples were collected from the mice at pre-
vaccination (0 month), 1, 2, 3, 4 and 5.5 months post-immunization. The
experiments were repeated two times and the data were presented as the mean
values ± SE.
Fig. 7. Inhibitory test of RBD binding to ACE2. Sera obtained from five mice
vaccinated with 3 doses of RBD-rAAV (labeled as M1–5) at 4 months post-
vaccination were detected for the inhibitory effect on the binding of RBD to
ACE2 by ELISA. Sera from five mice immunized with 3 doses of blank AAV
were applied to the assay as the negative control. The serum samples were tested
in duplicate and the data presented here were the mean values of the two tests.
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model.
SARS-CoV S protein is known to be responsible for
inducing host immune responses and virus neutralizing
antibodies in SARS infection (Buchholz et al., 2004; Gao et
al., 2003b; Hofmann et al., 2004; Nie et al., 2004; Yang et al.,
2004; Zheng et al., 2004). It has been reported that neutralizing
antibodies against SARS-CoV S protein are able to provide
protection against SARS-CoV infection (Bisht et al., 2004;
Bukreyev et al., 2004; Sui et al., 2004). Although multiple
fragments of S protein have been shown to be able to elicit
neutralizing activities (Keng et al., 2005; Zhang et al., 2004),
RBD, the receptor-binding domain to the functional virus
receptor ACE2, which contains multiple conformation-depen-
dent epitopes, can effectively induce highly potent protective
neutralizing antibodies (Chen et al., 2005; He et al., 2004b,
2005a). A recent study also demonstrated that the RBD region is
the main target in eliciting neutralizing antibodies in inactivated
SARS-CoV immunized rabbits, and an important immunogenic
site in patients infected with SARS-CoV (He et al., 2005b).
Therefore, RBD of SARS-CoV S protein was selected as the
target immunogen in our study for development of SARS-CoV
vaccines.
In the construction of the pRBD-AAV vector, the RBD gene
of SARS-CoV S was codon-optimized. Codon-optimization hasbeen used as a strategy to improve protein expression and
enhance immunogenicity of DNAvaccines in many viruses and
mycobacteria (Cheung et al., 2004; Ko et al., 2005; Moore et al.,
2004; Ramakrishna et al., 2004; Smith et al., 2004; Wang et al.,
2005a,b). A report by Gao et al. (2003a) has shown that codon-
optimization could increase the level of expression and enhance
the immunogenicity of the structural genes of the human
immunodeficiency virus type I (HIV-1). Frelin et al. (2004) has
also indicated that codon-optimization of hepatitis C virus
(HCV) genes results in an improvement in the immunogenicity
of HCV-based vaccines. Although we did not compare the
efficiencies between the codon-optimized RBD gene and the
wild-type RBD gene in this study, the high efficiency of our
RBD-rAAV vaccination may be partially attributed to that the
expression and immunogenicity of RBD has been improved by
the codon-optimization.
The reason why AAV was used to deliver and express the
RBD gene in our study was that it has been demonstrated to be a
promising tool for delivery of foreign genes due to its advantages
in high virus production and broad host range without causing
any known human diseases (Stilwell and Samulski, 2003; Wang
et al., 2000). Our results showed that as high as 5 × 1012 viral
particles/ml of RBD-rAAV could be produced by transfection of
293T cells. It was also confirmed that the recombinant RBD-
rAAV was able to efficiently infect different cell lines (Fig. 3)
and express the RBD protein in transduced cell lines, which was
recognized by a SARS-CoV neutralizing McAb (Fig. 4).
In the mouse model, vaccination with single dose of RBD-
rAAV elicited a high level of SARS-CoV-specific antibodies,
especially neutralizing antibodies, reaching the mean titer of
1:108 at 4 months post-immunization, which was higher than
that induced by the inactivated virus vaccination with or
without Alum (Fig. 5). It was further demonstrated that the
mouse sera induced by the RBD-rAAV vaccination were able
to effectively suppress RBD binding to ACE2 (Fig. 7),
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inhibition of the virus binding to its receptor on the host cell
membrane. It has been reported that levels of SARS-CoV
neutralizing antibody found in convalescent sera of recovered
SARS patients ranged from 1:40 to 1:1280 (Zheng et al.,
2004). Another study also shows that the titer of 1:100 of
SARS-CoV neutralizing antibody elicited by a recombinant
attenuated modified vaccinia virus Ankara (MVA) encoding
SARS S protein protected immunized mice from SARS-CoV
challenge (Bisht et al., 2004). Our results suggested that one
dose vaccination of RBD-rAAV may provide sufficient
protection against the SARS-CoV infection.
It had been found that, in some viral delivery systems, i.e.,
adenovirus and vaccinia virus systems, the primary immuniza-
tion could induce host immunity against the delivery viral
particle themselves, which would affect the efficacy of
subsequent repeated vaccinations (Liu and Muruve, 2003;
Muruve, 2004; Nasz and Adam, 2001). However, our results
showed that the primary vaccination with RBD-rAAV did not
affect the repeated vaccinations. The neutralizing antibody level
markedly increased after the mice were boosted twice, reaching
the mean titer of 1:512 that was 5-fold higher than the mice that
received one dose of vaccination (Fig. 6). This may be attributed
to that the low antigenicity of the AAV delivery vector used in
this study minimized the host immune response to the delivery
vector itself.
Compared to the inactivated SARS-CoV immunization,
SARS-CoV-specific antibodies induced by either single dose or
repeated RBD-rAAV vaccinations reached the highest level at
least 1–1.5 months later, but the vaccinations were able to
stimulate mice continuously producing SARS-CoV-specific
antibodies with an increasing neutralizing activity, at least until
the end point of our experiment (4 months for single dose and
5.5 months for repeated doses), indicating that the RBD-rAAV
vaccination can deliver a prolonged immune response (Figs. 5
and 6). This may be due to that the gene expression of the
recombinant AAV goes through a slow onset firstly, taking a
course of a few days or weeks, followed by persistent gene
expression for many months, which is supported by reports that
the AAV may long-term express foreign genes in vivo in
different organisms without resulting in significant toxicity
(Monahan and Samulski, 2000; Rabinowitz and Samulski,
1998; Smith-Arica and Bartlett, 2001). However, we cannot
conclude if the antibody response has reached the highest level
at the study end time and how long the high level of specific
antibodies will be maintained in these RBD-rAAV-vaccinated
mice, because we did not monitor the antibody responses for
more than 5.5 months post-immunization.
In summary, our study demonstrated that the live AAV
delivery system was an effective tool in delivery and expression
of the RBD gene of SARS-CoV in the mouse model. The single
dose of intramuscular immunization of RBD-rAAV induced
viral-specific antibody responses, whose titer was significantly
higher than that of the inactivated virus vaccination. The
repeated vaccination elicited a prolonged immune response,
resulting in an increase of SARS-CoV neutralizing antibody in
vaccinated mice up to the end point of this study. Anotheradvantage of the vaccines based on the live AAV delivery
system is that it may be used for mucosal immunization to
induce local immune response. It has been reported that high
titers of fecal HIV-specific IgA and neutralizing antibodies were
detected in HIV-rAAV immunized mice (Xin et al., 2001). A
study of RBD-rAAV intranasal vaccination is in progress to
further demonstrate the feasibility of the live AAV recombinant
vaccine in development of SARS vaccines.
Materials and methods
Construction of the AAV plasmid expressing RBD of
SARS-CoV S protein
Gene encoding the 193-aa of RBD of SARS-CoV S protein
was codon optimized using overlapping primers according to
the methods described previously (Gao et al., 2004; He et al.,
2004b; Fig. 1a). The codon optimized RBD gene was cloned
into the pMD18-T vector (Takara, Japan), which was used as
the template for the first-round PCR with the forward primer 5′-
CTGCTGGGGATGCTGGTCGCTAACATCACCAACCTG
TGTCCC-3′ and the reverse primer 5′-TATATCTCGAG-
CACGGTGGCGGGCGCGTTCAGG-3′ (XhoI restriction en-
zyme site underlined, no stop codon). The amplified RBD
fragment was then used as the template for the second-round
PCR to amplify CD5-RBD, in which the gene of the CD5 signal
peptide was ligated into the 5´ end of the RBD product, using
the forward primer 5′-AAGGATCCAGAAACCATGCCCAT-
GGGGTCTCTGCAACCGCTGGCCACCTTGTACCTGCTG-
3′ (BamHI restriction site underlined, start codon labeled in
bold), and the same reverse primer of the first round. The
amplified CD5-RBD was digested by BamHI and XhoI, and
subcloned into the MCS of the pAAV-IRES-hrGFP vector, in
which hrGFP from a novel marine organism was expressed as a
second open reading frame, and served as an indicator for the
expression of the inserted RBD gene and an evaluator for the
efficiency of transfection and infection in the subsequent
experiments (Fig. 1B). The constructed recombinant plasmid
was named as pRBD-AAV.
Production and purification of the AAVs
The RBD-rAAV and blank AAV were generated using the
AAV-Helper-Free-System following the manufacturer's instruc-
tions (Stratagene, USA). Briefly, 1 day before transfection,
293T cells were seeded into 100-mm tissue culture dishes and
maintained in Dulbecco's modified Eagle's medium (DMEM)
(Invitrogen, USA) supplied with 10% fetal calf serum (FCS)
(Invitrogen, USA). When 293T cells (providing the adenovirus
E1A gene) reached 70–80% confluence, the pRBD-rAAV or
pAAV plasmid was co-transfected with the pHelper plasmid
(providing the adenovirus E2A, E4, and VA RNA genes) and
the pAAV-RC plasmid (providing the AAV2 rep/cap genes) by a
calcium phosphate transfection method (Stratagene, USA).
Transfected cells were cultured at 37 °C with 5% CO2 and fresh
medium was added 10–12 h later. Both culture supernatant and
transfected cells were harvested 72 h after transfection.
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(2004) with some modifications. The harvested cells were lyzed
by sonication and shaken at 37 °C for 1 h after adding
chloroform and NaCl respectively to 10% and 1 mol/L. The
supernatant was incubated with PEG8000 (final concentration
10%) on ice for 1 h. The solutions from both cell lysate and
supernatant were centrifuged at 12,000 rpm for 15 min at 4 °C.
The pellets were re-suspended in phosphate-buffered saline
(PBS) buffer (pH 7.4) and then incubated with DNase I and
RNase A at the final concentration of 1 μg/ml on ice for 30 min,
followed by adding an equal volume of chloroform. The
aqueous phases containing the purified AAVs were collected
after centrifugation at 12,000 rpm for 5 min at 4 °C and stored
at −80 °C until use.
Titration of the AAVs
The titers of generated AAVs were determined by real-time
quantitative PCR using the forward primer 5′-ATTCTGAGTC-
CAAGCTAGGC-3′ and the reverse primer 5′-GCTTTT-
GTTCCCTTTAGTGAG-3′. Briefly, 10 μl of purified virus
stock was treated with protease K and sodium dodecyl sulfate
(SDS) at a final concentration of 0.3 mg/ml and 0.1%,
respectively. Viral DNA was extracted using DNA extraction
kit (Invitrogen, USA). The viral DNA with 10-fold serial
dilutions was mixed with the primers and LighterCycler
FastStart Reaction SYBR Green I reagent (Roche, USA). The
real-time quantification was carried out in a LightCycler System
(Roche, USA) with conditions of 95 °C for 10 min, 45 cycles of
95 °C for 10 s, 55 °C for 5 s and 72 °C for 10 s, followed by
60 °C for 15 s. pRBD-AAV plasmid in 10-fold serial dilutions
was used as the standard control.
Detection of the AAV infectivity
The infectivity of purified AAVs was tested in 293T and
HeLa cells (ATCC, USA) using fluorescence microscopy and
flow cytometry analysis. Purified virus was serially diluted in
serum-free medium and added to the cell cultures, which were
seeded in 96-well tissue culture plates 1 day before infection.
Fresh DMEM supplied with 5% FCS was added 2 h later and
continued the cultures at 37 °C for 1–4 days. After 72 h of
culture, the cells expressing hrGFP were observed under a
fluorescence microscopy (Olympus IX70, USA). Infection rates
of the AAVs in different cell lines were also monitored by
detecting the percentage of cells expressing hrGFP using a flow
cytometer (FACSCalibur, BD, USA).
Immunofluorescence assay
An immunofluorescence assay was performed to detect the
RBD expression in infected HeLa cells. Briefly, cells were
infected with 1 × 1010 particles of RBD-rAAV or blank AAV.
Fresh DMEM supplied with 5% FCS was added 24 h later and
continued the cultures for 48 h. Infected cells were fixed with
4% paraformaldehyde and incubated with McAb S1 (kindly
provided by Dr. B. Sun at the Shanghai Institutes for BiologicalSciences, Chinese Academy of Sciences) at dilution of 1:1000
for 1 h at room temperature, followed by three washes in PBS
and incubation with PE-conjugated goat anti-mouse IgG
(eBioscience, USA) for 30 min. After 3 washes, the cells
were detected for fluorescence.
Western blot assay
The expression of the RBD protein was also detected by a
Western blot analysis. Briefly, RBD-rAAV or blank AAV-
infected 293T and HeLa cells were harvested at 72 h after
infection. The cells were washed three times with PBS and
lyzed in cell lysis buffer [50 mM Tris, pH 7.5, 150 mM NaCl,
0.1% SDS, 2 mM EDTA, 0.5% NP-40, 10% glycerol and 1×
protease inhibitor cocktail (Roche, USA)]. The expressed RBD
was separated by 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred to nitrocellu-
lose membranes (Amersham Biosciences, USA). The blots were
blocked overnight with 5% skim milk in PBS containing 0.1%
Tween 20 (PBS-T) at 4 °C, followed by incubation with the
McAb-S1 at dilution of 1:2000 for 1 h at room temperature. The
blots were then washed three times and incubated with HRP-
conjugated goat anti-mouse IgG (DAKO, Denmark) for 1 h at
room temperature. Signals were visualized with ECL Western
blotting substrate reagents (Amersham Biosciences, USA) and
KODAK BioMax Scientific Imaging Film (Eastman Kodak).
Animal vaccinations and sample collection
Female BALB/c mice aged 6 weeks were used for the
vaccination. Mice were separated into 9 groups (5 to 10 mice/
group). They were intramuscularly (i.m.) vaccinated respec-
tively with: (1) one dose (1011 particles in 200 μl PBS) of RBD-
rAAV; (2) one dose (1011 particles in 200 μl PBS) of blank
AAV; (3 and 4) one dose (80 μg protein in 200 μl PBS) of
inactivated SARS-CoV with or without adjuvant (Alum)
prepared as described by Qu et al. (2005); (5) three doses of
RBD-rAAVwith the second dose at 2nd week and the third dose
at 2nd month; (6) three doses of blank AAVas a control of group
5; (7 and 8) three doses of inactivated SARS-CoV with or
without Alum at 1-month interval; (9) three doses of PBS as a
control of groups (7) and (8). Mouse sera were collected at 0, 1,
2 and 4 months post-vaccination for group 1 to 4, and at 0, 1, 2,
3, 4 and 5.5 months post-immunization for group 5 to 9, by
retro-orbital puncture under diethyl ether anesthesia.
ELISA
Specific antibodies against SARS-CoV in mouse sera were
tested by an enzyme-linked immunosorbent assay (ELISA)
using the commercial SARS-CoV antibody detection kit
(Beijing Genomics Institute, Beijing, China). Briefly, serially
diluted mouse sera were added to 96-well microtiter plates
coated with the protein mixture from SARS-CoV viral lysates.
The plates were incubated at 37 °C for 30 min, followed by four
washes with PBS-T. Bound antibodies were then reacted with
HRP-conjugated goat anti-mouse IgG (DAKO, Denmark) at
14 L. Du et al. / Virology 353 (2006) 6–1637 °C for 20 min. After four washes, the substrate 3,3′,5,5′-
tetramethylbenzidine (TMB) (Zymed, USA) was added to the
plates and the reaction was stopped by adding 1 N H2SO4. The
absorbance at 450 nm was measured by an ELISA plate reader
(Victor 1420 Multilabel Counter, PerkinElmer, USA).
Neutralization assay
Titers of neutralizing antibodies in mouse sera immunized
with RBD-rAAV, blank AAVor inactivated virus were detected
in Vero E6 cells as described by Qu et al. (2005). Briefly, Vero
E6 cells were seeded at 1 × 104 cells per well in 96-well culture
plates and grown at 37 °C overnight. Serial 2-fold dilutions of
serum samples were separately mixed with 100 TCID50 (50%
tissue-culture infectious dose) of SARS-CoV GZ50 strain
(GenBank accession no. AY304495), incubated at 37 °C for
1 h, and added to the monolayer of Vero E6 cells. In each assay,
a virus back-titration (virus in serial 2-fold dilutions with
medium), virus positive control (100 TCID50) and negative cell
controls with medium were also included in parallel with the
neutralization test. Cytopathic effect (CPE) was observed daily
and the endpoints were read and recorded up to 3 days post-
infection. The neutralizing antibody titer was determined based
on the highest dilution of each serum, which completely
suppressed CPE induced by the virus.
Inhibition of RBD binding to SARS-CoV receptor ACE2
Inhibitory effect of mouse anti-sera on RBD binding to the
receptor ACE2 was tested by an ELISA assay (He et al., 2004b,
2005a). Briefly, recombinant soluble ACE2 (R&D systems)
was coated to 96-well microtiter plates at 2 μg/ml concentration
in 0.1 M carbonate buffer (pH 9.6) and incubated at 4 °C
overnight. After blocking with 2% skim milk, 1 μg/ml of RBD-
Fc was added to the wells in the presence or absence of diluted
sera from RBD-rAAV and blank AAV-vaccinated mice and
incubated at 37 °C for 1 h. The plates were washed twice with
PBS-T and incubated with HRP-conjugated goat anti-human
IgG (Zymed, USA) at 37 °C for 1 h, followed by adding the
substrate TMB for detection.
Statistical analysis
All values were presented as means ± standard error (SE).
Statistical significance between RBD-rAAV and inactivated
SARS-CoV in single and repeated vaccinations was calculated
by Student's t test using Stata statistical software. P values less
than 0.05 were considered significant.Acknowledgments
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